Panzem® NCD
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Nov 1, 2006 → Nov 1, 2008
NCT ID
NCT00394810About Panzem® NCD
Panzem® NCD is a phase 2 stage product being developed by CASI Pharmaceuticals for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00394810. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00394810 | Phase 2 | Completed |
Competing Products
20 competing products in Prostate Cancer